Verdiva Bio
Clinical-stage biotech developing next-generation oral and injectable medicines for obesity and cardiometabolic disease.
verdivabio.com ↗Why it's here
Launched in January 2025 with a $411M Series A co-led by Forbion and General Atlantic, with OrbiMed and Lilly Asia Ventures participating.
source: biospace.com- Focus
- Obesity Therapeutics
- Founded
- 2024
- Total raised
- $411Msource: biospace.com
- Latest round
- Series A, $411M, Jan 2025
- Registered office
- 5 Swallow Place, Westminster W1B 2AFsource: verdivabio.com
- London presence
- HQsource: linkedin.com
- Investors
- Forbion (lead), General Atlantic (lead), Lilly Asia Ventures, Logos Capital, OrbiMedsource: biospace.com
- Nearest station
- Oxford Circus, 58 m
- Visas
- Licensed visa sponsor, listed as Verdiva Bio Limitedsource: gov.uk
- Elsewhere
- LinkedIn ↗
Verified 6 Oct 2026. How we verify · Suggest a fix
For Verdiva Bio
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/verdiva-bio"><img src="https://londonmempool.co.uk/badge/verdiva-bio.svg" alt="Verdiva Bio is listed on London Mempool" width="361" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.